Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?

Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BS.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):951-958. doi: 10.1016/j.ijrobp.2016.08.018. Epub 2016 Aug 22.


Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN.

Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25. No abstract available.


The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.


Letter to the editor re: positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.

Chalkidou A, Mikhaeel G, O'Doherty MJ, Marsden PK.

Mol Imaging Biol. 2013 Oct;15(5):521-2. doi: 10.1007/s11307-013-0628-9. Epub 2013 Mar 27. No abstract available.


Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators.

Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.


Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.


The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.

Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH.

Leuk Lymphoma. 2010 Aug;51 Suppl 1:28-33. doi: 10.3109/10428194.2010.500051. Review.


The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.

Fields PA, Mikhaeel G, Hutchings M, van der Walt J, Nunan T, Schey SA.

Haematologica. 2005 Dec;90(12):1711-3.


2-Fluorine-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography in the Pretreatment Staging of Hodgkin's Disease.

Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G.

Clin Positron Imaging. 1999 Nov;2(6):323. No abstract available.


Supplemental Content

Loading ...
Support Center